Flag of the European Union EU Clinical Trials Register Help

Clinical trials for tofacitinib

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44334   clinical trials with a EudraCT protocol, of which   7366   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    83 result(s) found for: tofacitinib. Displaying page 1 of 5.
    1  2  3  4  5  Next»
    EudraCT Number: 2018-001678-10 Sponsor Protocol Number: NL65853.029.18 Start Date*: 2019-06-06
    Sponsor Name:VU Medical Center
    Full Title: Tofacitinib: salvage therapy for patients with RCDII - a pilot study
    Medical condition: Refractory celiac disease type II
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Completed)
    Trial results: (No results available)
    EudraCT Number: 2017-002753-11 Sponsor Protocol Number: TofaSTAT17 Start Date*: 2018-01-25
    Sponsor Name:Tampere University Hospital
    Full Title: The effect of tofacitinib on the activity of JAK-STAT pathways in patients with rheumatoid arthritis (RA)
    Medical condition: Rheumatoid arthritis
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FI (Completed)
    Trial results: View results
    EudraCT Number: 2021-001560-14 Sponsor Protocol Number: FJD-RA-TOF-60418809 Start Date*: 2021-08-13
    Sponsor Name:FUNDACION JIMENEZ DIAZ HEALTH RESEARCH INSTITUTE
    Full Title: Single-center, open-label, uncontrolled clinical trial to evaluate the association between the expression of the JAK / STAT pathway and the response to tofacitinib in patients with refractory rheum...
    Medical condition: Refractory rheumatoid arthritis
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2016-001825-15 Sponsor Protocol Number: A3921192 Start Date*: 2017-02-16
    Sponsor Name:Pfizer Inc.
    Full Title: A PHASE 3B/4 RANDOMIZED DOUBLE BLIND PLACEBO CONTROLLED STUDY OF METHOTREXATE (MTX) WITHDRAWAL IN SUBJECTS WITH RHEUMATOID ARTHRITIS (RA) TREATED WITH TOFACITINIB 11MG MODIFIED RELEASE (MR) FORMULA...
    Medical condition: Rheumatoid Arthritis
    Disease: Version SOC Term Classification Code Term Level
    21.0 10028395 - Musculoskeletal and connective tissue disorders 10039073 Rheumatoid arthritis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SK (Completed) BG (Completed) BE (Completed) DE (Completed) GB (Completed) PL (Completed) ES (Completed) CZ (Completed) HU (Completed) IT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2020-004391-18 Sponsor Protocol Number: PI2020_843_0114 Start Date*: 2020-10-28
    Sponsor Name:CHU Amiens-Picardie
    Full Title: IMPACT OF ANTI-TNF, VEDOLIZUMAB AND TOFACITINIB ON AORTIC STIFFNESS, CAROTID INTIMA-MEDIA THICKNESS AND CARDIOVASCULAR RISK OF PATIENTS WITH ULCERATIVE COLITIS
    Medical condition: ulcerative colitis
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2018-002378-30 Sponsor Protocol Number: A3921210 Start Date*: Information not available in EudraCT
    Sponsor Name:Pfizer Inc.
    Full Title: OPEN-LABEL INDUCTION AND MAINTENANCE STUDY OF ORAL CP-690,550 (TOFACITINIB) IN CHILDREN WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS
    Medical condition: MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS
    Disease: Version SOC Term Classification Code Term Level
    20.1 100000004856 10045365 Ulcerative colitis LLT
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: SE (Trial now transitioned) BE (Trial now transitioned) DE (Trial now transitioned) SK (Completed) FR (Trial now transitioned) HU (Trial now transitioned) FI (Trial now transitioned) ES (Ongoing) NL (Trial now transitioned) PL (Trial now transitioned) IT (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2017-002784-18 Sponsor Protocol Number: 13005 Start Date*: 2018-07-24
    Sponsor Name:Clinical Trials and Research Governance
    Full Title: Safety and efficacy of Tofacitinib in ameliorating ischaemia reperfusion injury and allograft pancreatitis in solid organ transplantation – a pilot study
    Medical condition: Ischaemia reperfusion injury and allograft pancreatitis.
    Disease: Version SOC Term Classification Code Term Level
    20.1 10017947 - Gastrointestinal disorders 10066127 Ischaemic pancreatitis PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA)
    Trial results: (No results available)
    EudraCT Number: 2012-005645-20 Sponsor Protocol Number: A3921082 Start Date*: 2013-06-25
    Sponsor Name:Pfizer Inc. 235 East 42nd Street, New York, 10017
    Full Title: A PHASE 2B, MULTI-SITE, RANDOMIZED, DOUBLE-BLIND, VEHICLE-CONTROLLED, PARALLEL-GROUP STUDY OF THE EFFICACY, SAFETY, LOCAL TOLERABILITY AND PHARMACOKINETICS OF 2 DOSE STRENGTHS AND 2 REGIMENS OF TOF...
    Medical condition: Chronic Plaque Psoriasis
    Disease: Version SOC Term Classification Code Term Level
    16.0 100000004858 10071117 Plaque psoriasis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Completed)
    Trial results: View results
    EudraCT Number: 2011-002169-39 Sponsor Protocol Number: A3921092 Start Date*: 2014-03-26
    Sponsor Name:Pfizer Inc., 235 East 42nd Street, New York, NY 10017
    Full Title: A LONG-TERM, OPEN-LABEL EXTENSION STUDY OF TOFACITINIB (CP-690,550) FOR THE TREATMENT OF PSORIATIC ARTHRITIS Paediatric investigation plan numbers - (P/144/2010),(P/162/2011) and (P/0064/2012).
    Medical condition: Psoriatic arthritis (PsA)
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000018188 10037160 Psoriatic arthritis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed) HU (Completed) CZ (Completed) BG (Completed) SK (Completed) PL (Completed) ES (Completed) DE (Completed)
    Trial results: View results
    EudraCT Number: 2019-004179-38 Sponsor Protocol Number: PULMORA Start Date*: 2020-01-10
    Sponsor Name:Västra Götalandsregionen
    Full Title: Effects of tofacitinib vs methotrexate on clinical and molecular disease activity markers in joints and lungs in early rheumatoid arthritis
    Medical condition: Patients with early active rheumatoid arthritis
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004870 10039075 Rheumatoid arthritis and associated conditions HLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2017-002274-39 Sponsor Protocol Number: A3921288 Start Date*: 2017-12-08
    Sponsor Name:Pfizer Inc.
    Full Title: A PHASE 3B/4, MULTI-CENTER, DOUBLE-BLIND, RANDOMIZED, PARALLEL GROUP STUDY OF TOFACITINIB (CP-690,550) IN SUBJECTS WITH ULCERATIVE COLITIS IN STABLE REMISSION
    Medical condition: Ulcerative colitis
    Disease: Version SOC Term Classification Code Term Level
    20.1 100000004856 10045365 Ulcerative colitis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SK (Prematurely Ended) CZ (Prematurely Ended) BE (Completed) HU (Completed) NL (Prematurely Ended) GB (GB - no longer in EU/EEA) AT (Prematurely Ended) ES (Prematurely Ended) IT (Completed)
    Trial results: View results
    EudraCT Number: 2011-004581-14 Sponsor Protocol Number: A3921139 Start Date*: 2012-06-29
    Sponsor Name:Pfizer Inc.
    Full Title: A MULTI-CENTER, OPEN-LABEL STUDY OF CP-690,550 IN SUBJECTS WITH MODERATE TO SEVERE ULCERATIVE COLITIS
    Medical condition: Ulcerative colitis
    Disease: Version SOC Term Classification Code Term Level
    20.1 100000004856 10045365 Ulcerative colitis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: CZ (Completed) DK (Completed) HU (Completed) EE (Completed) GB (Completed) LV (Completed) BE (Completed) NL (Completed) ES (Completed) AT (Completed) DE (Completed) SK (Completed) PL (Completed) IT (Completed) HR (Completed)
    Trial results: View results
    EudraCT Number: 2021-005694-87 Sponsor Protocol Number: UCDCRC/21/01 Start Date*: 2022-10-25
    Sponsor Name:University College Dublin
    Full Title: A Randomised Pilot Study of the Safety and Efficacy of Tofacitinib (Xeljanz) in Improving Endoscopic Outcomes in Subjects with Ulcerative Colitis with Active, Chronic, Antibiotic Dependent or Refra...
    Medical condition: Subjects with Ulcerative Colitis with Active, Chronic, Antibiotic Dependent or Refractory Idiopathic Pouchitis
    Disease: Version SOC Term Classification Code Term Level
    20.0 10017947 - Gastrointestinal disorders 10036463 Pouchitis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2017-002018-29 Sponsor Protocol Number: A3921165 Start Date*: 2020-12-09
    Sponsor Name:Pfizer Inc.
    Full Title: EFFICACY, SAFETY, TOLERABILITY AND PHARMACOKINETICS OF TOFACITINIB FOR TREATMENT OF SYSTEMIC JUVENILE IDIOPATHIC ARTHRITIS (sJIA) WITH ACTIVE SYSTEMIC FEATURES IN CHILDREN AND ADOLESCENT SUBJECTS
    Medical condition: Systemic Juvenile Idiopathic Arthritis (sJIA)
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004859 10079454 Systemic juvenile idiopathic arthritis LLT
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: SK (Completed) PL (Completed) DE (Completed) BE (Completed) IT (Completed) NL (Prematurely Ended) SE (Prematurely Ended) HU (Completed)
    Trial results: View results
    EudraCT Number: 2011-004915-22 Sponsor Protocol Number: A3921145 Start Date*: 2012-08-03
    Sponsor Name:Pfizer Inc, 235 East 42nd Street, New York, New York 10017
    Full Title: A LONG-TERM, OPEN-LABEL FOLLOW-UP STUDY OF CP-690,550 FOR TREATMENT OF JUVENILE IDIOPATHIC ARTHRITIS (JIA)
    Medical condition: JUVENILE IDIOPATHIC ARTHRITIS (JIA)
    Disease: Version SOC Term Classification Code Term Level
    15.1 100000004859 10059176 Juvenile idiopathic arthritis LLT
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: HU (Completed) PL (Trial now transitioned) DE (Completed) SK (Completed) IT (Completed) ES (Ongoing) GB (GB - no longer in EU/EEA) BE (Trial now transitioned) NL (Prematurely Ended) SE (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2011-003668-55 Sponsor Protocol Number: A3921091 Start Date*: 2013-11-07
    Sponsor Name:Pfizer Inc., 235 East 42nd Street, New York, NY 10017
    Full Title: A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF THE EFFICACY AND SAFETY OF 2 DOSES OF TOFACITINIB (CP-690,550) OR ADALIMUMAB IN SUBJECTS WITH ACTIVE PSORIATIC ARTHRITIS. Paedi...
    Medical condition: Psoriatic arthritis (PsA)
    Disease: Version SOC Term Classification Code Term Level
    18.0 100000004859 10037160 Psoriatic arthritis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed) CZ (Completed) ES (Completed) SK (Completed) HU (Completed) DE (Completed) PL (Completed) BG (Completed)
    Trial results: View results
    EudraCT Number: 2019-000797-39 Sponsor Protocol Number: 201790 Start Date*: 2019-11-22
    Sponsor Name:GlaxoSmithKline Research & Development Limited
    Full Title: A 52-week, phase 3, multicentre, randomised, double blind, efficacy and safety study comparing GSK3196165 with placebo and with tofacitinib, in combination with methotrexate in participants with mo...
    Medical condition: Rheumatoid Arthritis
    Disease: Version SOC Term Classification Code Term Level
    21.0 10028395 - Musculoskeletal and connective tissue disorders 10039073 Rheumatoid arthritis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA) LV (Completed) ES (Completed) PL (Completed) LT (Completed) CZ (Completed) HU (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2019-001773-90 Sponsor Protocol Number: MiCROBPsA Start Date*: 2020-03-10
    Sponsor Name:AZIENDA OSPEDALIERA SANT'ANDREA
    Full Title: Metagenomic analysis of the gut microbiota in patients with psoriatic arthritis upon treatment with the jak-stat inhibitor tofacitinib: correlations with immunological, clinical and imaging markers
    Medical condition: Psoriatic Arthritis
    Disease: Version SOC Term Classification Code Term Level
    21.0 100000004859 10037160 Psoriatic arthritis LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: IT (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2020-002035-30 Sponsor Protocol Number: TOFACOV-2 Start Date*: 2020-05-15
    Sponsor Name:AZIENDA OSPEDALIERO-UNIVERSITARIA OSPEDALI RIUNITI DI ANCONA
    Full Title: TOFAcitinib plus Hydroxycloroquine vs Hydroxycloroquine in patients with early onset SARS-CoV2 (COVID-19) interstitial pneumonia: a multicenter randomized controlled open label trial
    Medical condition: SARS-CoV2 related Interstitial Pneumonia
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004862 10076502 Viral pneumonitis LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2011-004579-35 Sponsor Protocol Number: A3921095 Start Date*: 2012-05-01
    Sponsor Name:Pfizer Inc, 235 East 42nd Street, New York, New York 10017
    Full Title: A MULTICENTRE, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP STUDY OF ORAL CP-690,550 AS AN INDUCTION THERAPY IN SUBJECTS WITH MODERATE TO SEVERE ULCERATIVE COLITIS
    Medical condition: Moderate to severe active Ulcerative Colitis
    Disease: Version SOC Term Classification Code Term Level
    17.1 100000004856 10045365 Ulcerative colitis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed) CZ (Completed) HU (Completed) EE (Completed) DK (Completed) LV (Completed) BE (Completed) ES (Completed) NL (Completed) AT (Completed) DE (Completed) SK (Completed) PL (Completed) HR (Completed)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  3  4  5  Next»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Thu May 01 06:21:20 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA